| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 21.76% | Needham | $285 → $255 | Maintains | Buy |
| 10/27/2023 | 0.27% | Morgan Stanley | $220 → $210 | Maintains | Underweight |
| 10/03/2023 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 09/20/2023 | 5.05% | Morgan Stanley | $260 → $220 | Downgrades | Equal-Weight → Underweight |
| 09/05/2023 | 38.47% | TD Cowen | $270 → $290 | Maintains | Outperform |
| 08/03/2023 | 28.92% | TD Cowen | $350 → $270 | Maintains | Outperform |
| 08/02/2023 | 24.15% | Morgan Stanley | $295 → $260 | Maintains | Equal-Weight |
| 08/02/2023 | 35.13% | Baird | $322 → $283 | Maintains | Outperform |
| 08/02/2023 | — | Wolfe Research | Upgrades | Underperform → Peer Perform | |
| 08/02/2023 | 31.31% | Credit Suisse | $295 → $275 | Maintains | Outperform |
| 08/02/2023 | 36.08% | Needham | → $285 | Reiterates | Buy → Buy |
| 06/22/2023 | 40.86% | Credit Suisse | → $295 | Reiterates | Outperform → Outperform |
| 05/11/2023 | 67.12% | TD Cowen | $375 → $350 | Maintains | Outperform |
| 05/03/2023 | 40.86% | Morgan Stanley | $305 → $295 | Maintains | Equal-Weight |
| 05/03/2023 | 40.86% | Credit Suisse | $326 → $295 | Maintains | Outperform |
| 05/03/2023 | 53.75% | Baird | $365 → $322 | Maintains | Outperform |
| 05/03/2023 | 62.35% | Needham | $385 → $340 | Maintains | Buy |
| 04/25/2023 | 55.66% | Credit Suisse | $311 → $326 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 48.5% | Credit Suisse | $313 → $311 | Maintains | Neutral |
| 02/21/2023 | 90.99% | Stephens & Co. | $350 → $400 | Maintains | Overweight |
| 02/17/2023 | 83.83% | Needham | $330 → $385 | Maintains | Buy |
| 02/09/2023 | 49.45% | Credit Suisse | $319 → $313 | Downgrades | Outperform → Neutral |
| 12/20/2022 | 50.41% | Baird | $300 → $315 | Maintains | Outperform |
| 12/13/2022 | 24.15% | Morgan Stanley | $225 → $260 | Maintains | Equal-Weight |
| 12/13/2022 | 52.32% | Credit Suisse | → $319 | Initiates Coverage On | → Outperform |
| 12/01/2022 | — | Wolfe Research | Downgrades | Peer Perform → Underperform | |
| 11/03/2022 | 112.48% | UBS | $485 → $445 | Maintains | Buy |
| 11/02/2022 | 43.25% | Baird | $330 → $300 | Maintains | Outperform |
| 11/02/2022 | 57.57% | Needham | $450 → $330 | Maintains | Buy |
| 10/14/2022 | 7.43% | Morgan Stanley | $335 → $225 | Maintains | Equal-Weight |
| 08/04/2022 | 136.36% | UBS | $510 → $495 | Maintains | Buy |
| 08/03/2022 | 138.74% | Stephens & Co. | $600 → $500 | Maintains | Overweight |
| 08/03/2022 | 114.87% | Needham | $500 → $450 | Maintains | Buy |
| 05/23/2022 | 59.96% | Morgan Stanley | $400 → $335 | Upgrades | Underweight → Equal-Weight |
| 05/04/2022 | 110.09% | Baird | $540 → $440 | Maintains | Outperform |
| 05/04/2022 | 138.74% | Needham | $535 → $500 | Maintains | Buy |
| 04/14/2022 | 186.49% | UBS | $620 → $600 | Maintains | Buy |
| 04/12/2022 | 90.99% | Morgan Stanley | $470 → $400 | Maintains | Underweight |
| 04/04/2022 | 138.74% | JP Morgan | $530 → $500 | Upgrades | Neutral → Overweight |
| 03/08/2022 | 155.46% | Needham | $580 → $535 | Maintains | Buy |
| 02/11/2022 | 176.94% | Needham | $620 → $580 | Maintains | Buy |
| 02/08/2022 | 196.04% | Needham | $660 → $620 | Maintains | Buy |
| 11/03/2021 | 215.14% | Needham | $600 → $660 | Maintains | Buy |
| 09/23/2021 | 193.65% | UBS | $610 → $615 | Maintains | Buy |
| 09/13/2021 | 234.24% | Stephens & Co. | $600 → $700 | Maintains | Overweight |
| 08/04/2021 | 191.27% | UBS | $560 → $610 | Maintains | Buy |
| 08/04/2021 | 167.39% | Baird | $490 → $560 | Maintains | Outperform |
| 08/04/2021 | 186.49% | Needham | $580 → $600 | Maintains | Buy |
| 07/13/2021 | 167.39% | UBS | → $560 | Maintains | Buy |
| 07/02/2021 | 176.94% | Needham | $525 → $580 | Maintains | Buy |
| 05/05/2021 | 150.68% | Needham | $515 → $525 | Maintains | Buy |
| 04/21/2021 | 95.77% | Morgan Stanley | $380 → $410 | Downgrades | Equal-Weight → Underweight |
| 03/23/2021 | 167.39% | Northcoast Research | → $560 | Upgrades | Neutral → Buy |
| 02/19/2021 | 157.84% | UBS | $430 → $540 | Maintains | Buy |
| 02/12/2021 | 81.44% | Morgan Stanley | $335 → $380 | Maintains | Equal-Weight |
| 02/12/2021 | 145.91% | Needham | $445 → $515 | Maintains | Buy |
| 02/03/2021 | 112.48% | Needham | $340 → $445 | Maintains | Buy |
| 12/15/2020 | 59.96% | Morgan Stanley | $250 → $335 | Maintains | Equal-Weight |
| 11/04/2020 | 19.37% | Morgan Stanley | $240 → $250 | Maintains | Equal-Weight |
| 11/04/2020 | 62.35% | Needham | $320 → $340 | Maintains | Buy |
| 10/16/2020 | — | Stephens & Co. | Initiates Coverage On | → Overweight | |
| 10/13/2020 | 52.8% | Needham | $302 → $320 | Maintains | Buy |
| 07/29/2020 | 44.2% | Needham | $295 → $302 | Maintains | Buy |
| 07/23/2020 | 14.6% | Morgan Stanley | $217 → $240 | Maintains | Equal-Weight |
| 07/10/2020 | 40.86% | Needham | $250 → $295 | Maintains | Buy |
| 04/30/2020 | 19.37% | JP Morgan | → $250 | Downgrades | Overweight → Neutral |
| 04/29/2020 | 9.82% | Baird | $202 → $230 | Maintains | Outperform |
| 04/29/2020 | 3.61% | Morgan Stanley | $203 → $217 | Maintains | Equal-Weight |
| 03/19/2020 | 9.82% | Needham | $275 → $230 | Maintains | Buy |
| 03/16/2020 | -3.07% | Morgan Stanley | → $203 | Upgrades | Underweight → Equal-Weight |
| 03/12/2020 | 105.32% | UBS | → $430 | Initiates Coverage On | → Buy |
| 02/14/2020 | 25.1% | JP Morgan | $250 → $262 | Upgrades | Neutral → Overweight |
| 01/21/2020 | 31.31% | Needham | $255 → $275 | Maintains | Buy |
| 01/08/2020 | 3.61% | Morgan Stanley | → $217 | Downgrades | Equal-Weight → Underweight |
| 11/20/2019 | 26.53% | Imperial Capital | $245 → $265 | Maintains | Outperform |
| 11/05/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 10/31/2019 | 26.53% | Imperial Capital | $245 → $265 | Maintains | Outperform |
| 10/30/2019 | 28.92% | Baird | $235 → $270 | Maintains | Outperform |
| 10/30/2019 | 3.61% | Morgan Stanley | $205 → $217 | Maintains | Equal-Weight |
| 09/16/2019 | -2.12% | Morgan Stanley | $189 → $205 | Maintains | Equal-Weight |
| 08/27/2019 | 9.82% | Atlantic Equities | → $230 | Initiates Coverage On | → Overweight |
| 03/07/2019 | — | Berenberg | Initiates Coverage On | → Buy | |
| 11/12/2018 | -2.12% | Baird | $175 → $205 | Maintains | Outperform |
What is the target price for Zebra Technologies (ZBRA)?
The latest price target for Zebra Technologies (NASDAQ: ZBRA) was reported by Needham on November 1, 2023. The analyst firm set a price target for $255.00 expecting ZBRA to rise to within 12 months (a possible 21.76% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zebra Technologies (ZBRA)?
The latest analyst rating for Zebra Technologies (NASDAQ: ZBRA) was provided by Needham, and Zebra Technologies maintained their buy rating.
When is the next analyst rating going to be posted or updated for Zebra Technologies (ZBRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zebra Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zebra Technologies was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating Zebra Technologies (ZBRA) correct?
While ratings are subjective and will change, the latest Zebra Technologies (ZBRA) rating was a maintained with a price target of $285.00 to $255.00. The current price Zebra Technologies (ZBRA) is trading at is $209.43, which is out of the analyst's predicted range.